The results of the IMmotion150 trial, a phase II trial looking at the effectiveness of atezolizumab plus bevacizumab combination as first- or second-line treatment for metastatic renal cell carcinoma (RCC), were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago yesterday.

Three hundred and five (305) people with untreated metastatic RCC were randomised to receive atezolizumab plus bevacizumab combination, atezolizumab alone, or sunitinib alone to look at the efficacy and safety of these treatments. 54% of of the patients were positive for the PD-L1 receptor. Of these patients, the median progression-free survival (PFS) was 14.7 months with the atezolizumab plus bevacizumab combination, 5.5 months with atezolizumab alone, and 7.8 months with sunitinib alone. 60% of patients receiving atezolizumab alone and 78% of patients receiving sunitinib alone, and whose cancer progressed, went on to receive the atezolizumab plus bevacizumab combination. In these patients, who receive treatment with the combination in the second-line, overall response rates were 24% and 28%, respectively.

These results demonstrate encouraging activity of the atezolizumab plus bevacizumab combination in the first- and second-line setting for patients with metastatic RCC. 

Read more here and read the ASCO abstract here